Raiffeisen Bank International AG Acquires 6,673 Shares of Medtronic PLC $MDT

Raiffeisen Bank International AG increased its holdings in shares of Medtronic PLC (NYSE:MDT) by 18.7% in the third quarter, Holdings Channel.com reports. The fund owned 42,344 shares of the medical technology company’s stock after buying an additional 6,673 shares during the quarter. Raiffeisen Bank International AG’s holdings in Medtronic were worth $3,979,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of MDT. Empirical Financial Services LLC d.b.a. Empirical Wealth Management lifted its position in shares of Medtronic by 28.7% during the third quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 5,511 shares of the medical technology company’s stock worth $525,000 after purchasing an additional 1,230 shares during the last quarter. Lion Street Advisors LLC purchased a new position in Medtronic in the 3rd quarter worth about $311,000. Bridgewater Advisors Inc. lifted its holdings in Medtronic by 17.3% during the 3rd quarter. Bridgewater Advisors Inc. now owns 3,362 shares of the medical technology company’s stock valued at $303,000 after buying an additional 496 shares in the last quarter. Berkeley Capital Partners LLC boosted its position in Medtronic by 1.2% in the 3rd quarter. Berkeley Capital Partners LLC now owns 31,994 shares of the medical technology company’s stock valued at $3,047,000 after buying an additional 376 shares during the period. Finally, Woodley Farra Manion Portfolio Management Inc. grew its stake in Medtronic by 2.4% in the 3rd quarter. Woodley Farra Manion Portfolio Management Inc. now owns 46,057 shares of the medical technology company’s stock worth $4,419,000 after acquiring an additional 1,080 shares in the last quarter. Hedge funds and other institutional investors own 82.06% of the company’s stock.

Key Stories Impacting Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Regulatory/coverage win in Japan for Medtronic’s Symplicity Spyral renal denervation device and management commentary that the company is investing in rollout and hiring to support market development — supports revenue upside from a growing hypertension therapy. Medtronic’s blood pressure device wins coverage nod in Japan
• Positive Sentiment: Analyst upgrade: Mizuho moved Medtronic to a “strong-buy,” which can support buying interest and short-term momentum. Mizuho upgrade reported via Zacks
• Neutral Sentiment: Industry growth tailwinds — a separate report highlights expansion in non‑invasive therapies (HIFU) and robotics/image‑guided systems; positive for device sector demand but not a direct Medtronic headline. HIFU Market Competitive Landscape Report 2025
• Neutral Sentiment: Competitive update — Intuitive Surgical (ISRG) reports faster international procedure growth, which underscores competitive dynamics in robotics and could pressure Medtronic’s robotics expectations over time. ISRG’s International Growth Outpaces US
• Neutral Sentiment: Company commentary and Q3 earnings materials are out (transcript available) showing mixed results: solid robotics wins but offset by some legal and expense items — provides context for guidance and valuation debate. Medtronic (MDT) Q3 2026 Earnings Call Transcript
• Negative Sentiment: Multiple broker notes lowered expectations or targets (JPMorgan, Robert W. Baird; Leerink cut its target to $119) — analyst downgrades/target cuts weigh on sentiment and can amplify selling. JPMorgan low expectations
• Negative Sentiment: Planned layoffs: Medtronic will cut 81 roles at a California diabetes site as it readies the diabetes spin‑out; restructuring adds near‑term execution risk and uncertainty around the separations. Medtronic to cut 81 employees at California diabetes site
• Negative Sentiment: Broader skepticism in media pieces discussing mixed quarterly results, legal exposure and whether recent wins materially change Medtronic’s investment case — fuels analyst disagreement and investor caution. Mixed Q3 Results, Robotics Win and Legal Hit

Analysts Set New Price Targets

Several analysts have recently weighed in on MDT shares. Mizuho raised shares of Medtronic to a “strong-buy” rating in a research note on Wednesday. UBS Group reaffirmed a “neutral” rating and set a $104.00 target price on shares of Medtronic in a research report on Wednesday, February 4th. Weiss Ratings reiterated a “buy (b-)” rating on shares of Medtronic in a report on Monday, December 29th. Sanford C. Bernstein raised their price target on Medtronic from $111.00 to $112.00 and gave the company an “outperform” rating in a research note on Friday, January 9th. Finally, The Goldman Sachs Group set a $111.00 price objective on shares of Medtronic and gave the stock a “neutral” rating in a research note on Wednesday, November 19th. One analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have given a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $110.84.

Medtronic Trading Down 0.7%

MDT opened at $96.88 on Friday. The company has a current ratio of 2.42, a quick ratio of 1.80 and a debt-to-equity ratio of 0.57. The firm has a market cap of $124.20 billion, a price-to-earnings ratio of 26.99, a PEG ratio of 2.43 and a beta of 0.71. Medtronic PLC has a 12 month low of $79.55 and a 12 month high of $106.33. The stock has a fifty day moving average price of $99.04 and a 200-day moving average price of $96.70.

Medtronic (NYSE:MDT) last posted its earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.34 by $0.02. The company had revenue of $9.02 billion for the quarter, compared to analyst estimates of $8.89 billion. Medtronic had a return on equity of 14.88% and a net margin of 13.00%.The firm’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.38 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, equities research analysts anticipate that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Medtronic Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, January 16th. Investors of record on Friday, December 26th were paid a dividend of $0.71 per share. This represents a $2.84 annualized dividend and a dividend yield of 2.9%. The ex-dividend date was Friday, December 26th. Medtronic’s payout ratio is 79.11%.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).